financetom
Business
financetom
/
Business
/
Why ProFrac Shares Are Down Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why ProFrac Shares Are Down Today
Mar 13, 2024 9:47 AM

ProFrac Holding Corp. ( ACDC ) shares are trading lower after the company reported fourth-quarter FY23 results.

Revenue of $489 million missed the consensus of $594.97 million. Adjusted EBITDA of $110 million declined from $263.4 the prior year quarter.

The company reported a net loss of $(99.1) million vs. an income of $40.9 million the prior year quarter.

In the quarter, operating cash flow was $43 million, and capital expenditures were $33 million.

As of Dec. 31, 2023, ProFrac ( ACDC ) had $103 million of liquidity, including $19 million in cash and cash equivalents (excluding Flotek) and $83 million of availability under its asset-based credit facility.

Outlook: ProFrac ( ACDC ) expects higher profitability levels in 2024 in the Stimulation Services segment, with the projected higher fleet count, increased pumping hours, and the cost actions anticipated to offset any pricing pressures.

In the Proppant Production segment, the company anticipates modest improvement to mine utilization in the first quarter of 2024, with pricing per ton in the $25-$30 range and further improvement in utilization to 65%-75% in the second quarter of 2024.

Matt Wilks, executive chairman said, “Our fourth quarter results were challenged, as we expected, due to softness that persisted throughout the second half of the year.”

“To start the year, in January we surpassed our highest pumping efficiency since the fourth quarter of 2022 and in February we pushed the bar even higher as we increased our pumping hours per active fleet to the highest level ever recorded at ProFrac ( ACDC ), nearly 20% over our 2023 average.”

ACDC Price Action: Profrac Holding ( ACDC ) shares are down 0.94% at $7.86 at last check Wednesday. 

Read Next: Why Plug Power Shares Are Slumping Today

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
1911 Gold Provides High-Grade Intersections from True North Gold Project in Manitoba
1911 Gold Provides High-Grade Intersections from True North Gold Project in Manitoba
Nov 11, 2025
08:09 AM EST, 11/11/2025 (MT Newswires) -- 1911 Gold ( AUMBF ) reported Tuesday the latest high-grade assays from the True North gold project within the Rice Lake property in Manitoba. Highlights from the San Antonio West target include 24.83 grams per tonne (g/t) gold over 2.60 meters, including 46.00 g/t gold over 1.00 meters, including 63.20 g/t gold over...
Lithia Buys Elite Porsche, Audi Stores In High-End LA Markets
Lithia Buys Elite Porsche, Audi Stores In High-End LA Markets
Nov 11, 2025
Lithia & Driveway, part of Lithia Motors, Inc. ( LAD ) , announced on Tuesday the acquisition of Porsche Beverly Hills and Audi Santa Monica dealerships. Lithia Motors ( LAD ) is the parent entity, while Lithia & Driveway reflects its combined physical dealership network and online retail platform. The addition of these two premium stores is expected to contribute...
Kits Eyecare Reports Record Sales Week With Revenue Up 27% to $4.5 Million
Kits Eyecare Reports Record Sales Week With Revenue Up 27% to $4.5 Million
Nov 11, 2025
08:07 AM EST, 11/11/2025 (MT Newswires) -- Kits Eyecare ( KTYCF ) Tuesday announced record-breaking results for the week of Nov. 1 to Nov. 8. Total sales jumped 27% to $4.48 million, with repeat customers contributing 66% of total revenue. The company said 10,000 glasses were ordered, and glasses revenue rose 50%. Marketing spend took up 14.5% of revenue, or...
EnGene's Mid-Stage Trial Shows Improved Complete Response Rate in Non-Muscle Invasive Bladder Cancer Patients
EnGene's Mid-Stage Trial Shows Improved Complete Response Rate in Non-Muscle Invasive Bladder Cancer Patients
Nov 11, 2025
08:09 AM EST, 11/11/2025 (MT Newswires) -- EnGene ( ENGN ) said Tuesday that additional preliminary data from the pivotal cohort of its mid-stage trial of detalimogene voraplasmid showed an improved complete response rate of 62% in six months for patients with high-risk, Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer patients with carcinoma in situ. The data also showed low...
Copyright 2023-2026 - www.financetom.com All Rights Reserved